Lahav Gil

Lahav Gil is a Canadain-Israeli medtech executive, entrepreneur and investor, with deep roots in technology, design and operations.

Lahav began his career during the late 80s as an industrial designer in the Israeli technology sector. He immigrated to Canada in 2000. He has over three decades of experience as a founder, technology innovator, entrepreneur, executive and investor, mostly in the medtech/biotech space. Over that time, Lahav has contributed to the development and launch of over 200 technology products. He has founded several companies and sold two. Most notably, he founded the Kangaroo Group (ISO 13485) and invested fifteen years in building it into a major Canadian brand for medtech innovation, contract manufacturing, and medtech startup acceleration. In 2017, Lahav sold Kangaroo to its chief comparable, Starfish Medical. During the 7 years prior to selling, Lahav turned the Kangaroo Group into a private incubator, deploying the Kangaroo Group know-how and infrastructure as investment capital into startups. After selling Kangaroo, he orchestrated successful turnarounds at Relay Medical and UX Data Sciences.

Over his career, Lahav has advised numerous startups in both official and informal capacities. He currently operates as a mentor-angel, working with CEOs of medtech startups on advancing science and technology into products of meaningful clinical utility and building investable, acquirable companies. Most importantly he works with the founders on their own transition from a technology focus to a clinical and business-journey focus.

Lahav chairs the boards of three medtech startups; Pulsemedica, Arma Biosciences and Oxygenium, as well as co-founding a mountain bike startup together with his son Ariel. He is the author of the Cathedral Framework, a stakeholder-centric systems approach to life-sciences venture design/building.

Lahav splits his time between Toronto and Tel Aviv. He is deeply interested in a thriving future for humanity, sustainability, ethics, values-based leadership and innovation culture.